Drug clearance (sometimes called "metabolic clearance rate") is an important pharmacokinetic parameter useful in the evaluation of hepatic or renal function and adjustment of drug dosage regimens. It was first defined in 1956 by Hoenig and Schiick 3 as the ratio of intravenous dose to the area under the plasma concentration-time curve from zero to infinity, which has since been used to calculate the renal clearance of 125I-iothalamate, I the plasma clearance of penicillin, 10 and the metabolic clearance rates of cortisol 5 and prednisolone. 4 Although this formula is not based on the Unfortunately, too many investigators inappropriately assume a one-compartment open model by using V dapp or V dext to calculate clearance for data which are perhaps better fitted to a *v dspp is often used interchangeably with V dex', the extrapolated volume of distribution.
assumption of a pharmacokinetic model, model-specific formulas have been derived. For the one-compartment open model, clearance is simplified to the product of Al (the apparent first-order elimination rate constant) and V dapp * (the apparent volume of distribution). Clearance for all other linear compartment models is equal to the product of Al and V darea (the volume of distribution at any time during the terminal log-linear phase of drug elimination). (See Appendix, Equations 1 to 11 for derivations. )
Unfortunately, too many investigators inappropriately assume a one-compartment open model by using V dapp or V dext to calculate clearance for data which are perhaps better fitted to a *v dspp is often used interchangeably with V dex', the extrapolated volume of distribution. Although it has been shown that error is introduced when parameter estimates for multicompartment data are calculated by equations for the simple one-compartment system,9. 14 the magnitude and significance of this error have not been demonstrated. This study was undertaken to quantitate the degree of error introduced when drug clearance is calculated by the use of an incorrect pharmacokinetic model. By purposely assuming a one-compartment model (8) to calculate serum clearance for data described by a biexponential equation, we show not only the degree of error in the calculated clearance values, but, more importantly, the dependence of percentage error on renal function. The importance of model-independent pharmacokinetic parameter calculations is discussed.
Methods
The pharmacokinetic data of 131 1_0_ iodohippurate (OIH I31 1) and 1251-iothalamate (IOp 25 1) from Welling and co-workers l5 were used in this investigation. In the original study, male patients were divided into three groups on the basis of renal function: group 1 (53 patients) was designated as normal with serum creatinines equal to or less than 1.5 mg per 100 ml; group 2 (21 patients), with ~erum creatinines between 1.6 and 2.5 mg per 100 ml, was designated moderately uremic; and group 3 where V darea • Al is the true serum clearance and Al is the smallest rate constant. The means, standard deviations, and coefficients of variation were calculated for all parameters, and linear regression analysis was done to relate percentage error in clearance calculation to the endogenous creatinine clearance.
Results
The mean pharmacokinetic parameters on OlH Tables I and  II . Included in the tables are the endogenous creatinine clearance and the percentage error introduced by drug clearance calculations based on the assumption of a one-compartment model. With both drugs, the mean percentage error was large in normal patients, less in patients with moderate uremia, and quite small in severely uremic individuals. The relationship of percentage error in calculation of drug clearances to the endogenous creatinine clearance is illustrated in Fig. 1. Fig. 2 graphically depicts the effect of renal impairment, represented by the three patient groups, on the mean percentage error. The difference among the mean percentage errors for the three groups was significant (p < 0.005) for both drugs, using the Kruskal-Wallis H test. lows that clearances calculated using V dext for data described by a biexponential equation will also be overestimated as verified by our results, where the mean overestimation for OIH131I was as high as 75%. Equation 13 in the appendix shows that the degree of error introduced depends on the relative values of the coefficients and exponents of the biexponential equation describing the system, or it depends on how "two-compartment" the system is. In renal failure, the elimination rate constant, A\> is smaller, thus decreasing the ratio indicative of degree of error. This is demonstrated in Figs. 1  and 2 where the percentage error is seen to decrease as renal function decreases. The clinical importance of this error cannot be overlooked. Because the magnitude of error may be large, and because it depends on the degree of renal function, the use of the onecompartment formula for data fitted by a biexponential equation may be unreliable, especially for drugs excreted primarily by the kidney. As overestimation of clearance increases with increasing renal function, the use of V dext could give rise to drug overdoses in normal individuals. Alternatively, if the calculated dose produces a required therapeutic effect in normals, dose adjustment in uremic patients based on clearance values using V dext may lead to therapeutic failure due to disproportionate dose reduction. If serum or plasma clearances are used to evaluate renal function, as for OIH131I and IOP25, overestimation of the clearances will indicate that the renal function is better than it actually is. In general, because plasma or serum clearance is often used to adjust drug dosage and evaluate renal function, a large degree of error in its calculation may adversely affect a patient's therapeutic regimen.
Because the assumption of an incorrect pharmacokinetic model for a set of blood concentration vs time data may lead to a high degree of error in clearance calculations, an alternative method for these calculations might be used. Due to the uncertainty of the correctness of a particular pharmacokinetic model, another approach to the problem would be one that is "model-independent." Instead of assuming a model and basing parameter calculations on that model, one can find the polyexponential equation that best fits the experimental data and calculate clearance directly from the coefficients and exponents of that equation. 13 Errors associated with assumption of an incorrect pharmacokinetic model may be eliminated in this manner. [1]
[2]
[3]
The general equation for finding the area under the concentration-time curve from zero to infinity is simply the sum of the ratio of coefficients to their exponents: and for data described by a biexponential equation: [7] [8] [9] [10] [ 11] One can see that the clearance formula for a one-compartment model cannot be applied to data described by anything except a monoexponential equation. If a one-compartment model is assumed for polyexponential data, the ratio of clearance calculated by (V dext • AI) to the true clearance (V darea . AI) is given by:
Al (I CJ Ai) [12] When a one-compartment model is erroneously assumed for data described by a biexponential equation, this ratio is equal to: [ 13] Thus, it can be seen that the error in calculation of clearance by assumption of a one-compartment open model depends on the values of both coefficients C I and C 2 , and both rate constants, Al and 1.. 2 , 
